The Green Cross Corporation

Morinaga Milk Industry Co., Ltd.

Satoshi Funakoshi

Yahiro Uemura

Tadakazu Suyama

Takao Ohmura

Yasuo Ueda

Hirofumi Arimura

Yoshio Kagitani

Katuhiro Uriyu

Hiroshi Morise

Muneo Yamada

Morio Kuboyama

Yutaka Hirao

Nobuya Yanai

Tsunekazu Fukushima

Yusei Shiraga

Akimasa Ohmizu

Takao Omura

Takeshi Ohshiro

Kenji Tanaka

Yoshio Arakawa

Katsuhiro Ogasa

Masayuki Nishida

Daisuke Satoh

Atuyuki Takanabe

Hajime Yokota

Takashi Goto

Shirou Komeda

Kazuo Morimoto

Satoshi Morimoto

Yoshiaki Kano

Tunetaka Nakajima

Takuji Doi

Takao Oomura

Mitsugu Fujii

Takuji Hanamura

Terufumi Fujiwara

Tunekazu Fukushima

Midori Nagatomo

Katashi Nakane

Akio Yamane

Tomiyuki Matsunaga

An alkali metal hydrogensulfite or sulfite is effective for controlling a local injury such as inflammation and vein injury occurring on the injection of an antitumor benzodiazepine compound of the formula ##STR1## wherein R.sub.1 denotes hydrogen atom, or acyl, carbamyl, or alkoxycarbonyl group; R.sub.2 denotes hydrogen atom or acyl group; and R.sub.3 denotes sulfinic acid rest, SO.sub.2 X, or sulfonic acid rest, SO.sub.3 X, X meaning hydrogen, alkali metal or alkaline earth metal. An aqueous solution containing the both can be administered by injection.

Injectable aqueous solution containing hydrogensulfite and/or sulfite

A dry .gamma.-globulin preparation capable of intravenous injection which is obtainable by polyethylene glycol fractionation of plasma is improved in its water-solubility and stability against increase of anticomplement activity and decrease of antibody titer by purifying the .gamma.-globulin fraction with respect to protein to render the residual polyethylene glycol substantially not detectable in its 5% W/V solution, adding 0.2 to 2 parts by weight of glucose based on 1 part of .gamma.-globulin, and lyophilizing its solution.

Gamma-globulin preparation for intravenous administration

A reagent for determination of human blood coagulation factor XIII for reversed passive hemagglutination reaction which comprises sensitized erythrocytes prepared by sensitizing animal erythrocytes with specific anti-human factor XIII antibody, and a kit using the reagent are disclosed.

Reagent for determination of blood coagulation factor XIII

Benzodiazepine derivative represented by the following general formula or pharmaceutically acceptable salt thereof: ##STR1## wherein R.sup.1 is --COR.sup.4 (R.sup.4 is a carboxylic acid residue) or an alkyl or aralkyl group (these groups have a substituent selected from a carboxyl group, an amino group and a cyano group), R.sup.2 is a lower alkyl group and R.sup.3 is a hydrogen atom or a lower alkyl group. The above compound is low in toxicity and has an antitumor activity.

1H-pyrrolo-[2,1-C][1,4]benzodiazepine-2-acrylamide compounds having

A lyophylized cold insoluble globulin preparation can be prepared in stable condition and in short time by lyophylizing an aqueous solution of a cold insoluble globulin in the presence of albumin and a neutral amino acid, a monosaccharide, a disaccharide or a sugar alcohol. The preparation dissolves in water without occurrence of turbidity and is usable for injection.

Method of lyophilizing cold insoluble globulin

A process for producing a hepatitis B infection preventing vaccine containing hepatitis B surface antigen as a main component thereof which comprises removing human plasma components possibly causing adverse effects and components capable of causing hepatitis B infection by incorporating steps of fractionation using ammonium sulfate, adsorption on a colloidal silicate and fractionation using polyethylene glycol into the purification stage after heat treatment and further carrying out a treatment for infectivity inactivation without causing any antigenicity impairment.

Process for producing a hepatitis B infection preventing vaccine

Physiologically active substances such as antibiotics can preferentially be carried to a morbid part, for example, injured tissue and neoplastic cell proliferation site by administering its complex with fibronectin to repair the morbid part. The complex is prepared by the reaction between the physiologically active substance and the fibronectin with or without intervention of a protein cross-linking agent.

Fibronectin-physiologically active substance complex and method of

Process for recovering interferon

Human urine-origin colony-stimulating factor and kallikrein are separated in pure form, respectively, from an aqueous solution thereof, such as a urinary protein-concentrated solution by subjecting the solution added with a stabilizer such as octyl-phenoxypolyethoxyethanaol or polyethylene glycol both having a molecular weight of 1,000-10,000, to high-performance gel filtration effective in molecular exclusive limit of 10.sup.5 -5.times.10.sup.5 as determined with globular protein.

Method of preparation of human urine origin colony-stimulating factor

Cold insoluble globulin which may have hepatitis virus activity can be virus-inactivated with keeping at a minimum the damage of the cold insoluble globulin by heating its aqueous solution at 50.degree. to 80.degree. C. for 5 to 20 hours in the presence of 10% (W/V) or more of at least one principal stabilizer of neutral amino acids, monosaccharides, disaccharides, and sugar alcohols with or without 10% (W/V) or more of at least one auxiliary stabilizer of salts of hydrocarbon carboxylic acids or hydroxyhydrocarbon carboxylic acids both having 3 to 10 carbon atoms.

Process for heat treatment of aqueous solution containing cold insoluble

A process for preparing immunoglobulin suitable for intravenous injection, comprising treating with an acid a plasma or fraction I+II+III, fraction II+III, fraction II, or fraction III (hereinafter these are sometimes referred collectively to as starting material) obtained from plasma by Cohn's cold alcohol fractionation method, and subjecting to fractionation using an alkylene oxide polymer or copolymer having a molecular weight of 2,000 to 20,000.

Process for preparing immunoglobulin suitable for intravenous injection

A method for stabilizing plasminogen which comprises adding a physiologically acceptable inorganic salt to a plaminogen-containing aqueous solution to give a final concentration of the salt of 0.002 to 0.4 M.

Method for stabilizing plasminogen

A process for recovering interferon which comprises contacting a solution containing an interferon produced by the induced cells of human origin with a water-insolubilized sulfated polysaccharide to allow the interferon to be adsorbed on the water-insolubilized sulfated polysaccharide and then selectively eluting the interferon with an aqueous solution of an inorganic salt.

Antithrombin preparation and process for the production thereof

A method of treating hypoproteinemia is disclosed in which an enteric film coated IgA-rich gamma globulin is administered orally to a person suffering therefrom until total serum content and plasma content are restored. The film coating is soluble in neutral or alkaline media by insoluble in acid media.

Employment of enteric coated IgA for hypoproteinemia in intestinal

Growing community of inventors

Katano, Japan

Satoshi Funakoshi